Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $81000.0.

  • Orchestra BioMed Holdings' Depreciation & Amortization (CF) rose 657.89% to $81000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $329000.0, marking a year-over-year increase of 1114.86%. This contributed to the annual value of $308000.0 for FY2024, which is 731.71% up from last year.
  • Orchestra BioMed Holdings' Depreciation & Amortization (CF) amounted to $81000.0 in Q3 2025, which was up 657.89% from $81000.0 recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Depreciation & Amortization (CF) peaked at $84000.0 during Q4 2024, and registered a low of $48000.0 during Q1 2022.
  • Its 4-year average for Depreciation & Amortization (CF) is $70800.0, with a median of $73000.0 in 2023.
  • In the last 5 years, Orchestra BioMed Holdings' Depreciation & Amortization (CF) soared by 4791.67% in 2023 and then surged by 136.99% in 2024.
  • Quarter analysis of 4 years shows Orchestra BioMed Holdings' Depreciation & Amortization (CF) stood at $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then grew by 16.67% to $84000.0 in 2024, then dropped by 3.57% to $81000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $81000.0 for Q3 2025, versus $81000.0 for Q2 2025 and $83000.0 for Q1 2025.